Cytokinetics CYTK Liabilities Fair Value Adjustment
Liabilities Fair Value Adjustment at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueAdjustment.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's liabilities fair value adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's liabilities fair value adjustment?
- Cytokinetics (CYTK) reported liabilities fair value adjustment of -$1.6M in Q1 2026.
- How has Cytokinetics's liabilities fair value adjustment changed year-over-year?
- Cytokinetics's liabilities fair value adjustment decreased by 141.0% year-over-year, from $3.9M to -$1.6M.
- What does liabilities fair value adjustment mean?
- Accounting adjustments made to reflect the current market value of specific liabilities.
- How do you interpret liabilities fair value adjustment?
- Adjustments are often non-cash and driven by market factors; they indicate changes in the estimated value of future obligations.
- How does liabilities fair value adjustment compare across companies?
- Highly specific to companies with complex balance sheets or contingent liabilities related to acquisitions or financing.